Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism

被引:3
作者
Wang, Yi-Jun [1 ]
Xie, Xiao-Li [1 ]
Liu, Hong-Qun [2 ]
Tian, Hui [1 ]
Jiang, Xiao-Yu [1 ]
Zhang, Jiu-Na
Chen, Sheng-Xiong [3 ]
Liu, Ting [4 ]
Wang, Shu-Ling [4 ]
Zhou, Xue [1 ]
Jin, Xiao-Xu [1 ]
Liu, Shi-Mao [5 ]
Jiang, Hui-Qing [1 ]
机构
[1] Hebei Med Univ, Hosp 2, Dept Gastroenterol, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China
[2] Univ Calgary, Liver Unit, Calgary, AB T1W 0K6, Canada
[3] Hebei Med Univ, Hosp 2, Dept Hepatobiliary Surg, Shijiazhuang 050000, Hebei, Peoples R China
[4] Hebei Med Univ, Hosp 1, Dept Gastroenterol, Shijiazhuang 050000, Hebei, Peoples R China
[5] Hebei Youfu Hosp, Dept Gastroenterol, Shijiazhuang 050000, Hebei, Peoples R China
关键词
Prostaglandin F(2 alpha)synthase; Colorectal cancer; Oxaliplatin; Drug resistance; DNA damage; RECTAL-CANCER; DRUG-RESISTANCE; CISPLATIN; AKR1C3; EXPRESSION; OVEREXPRESSION; INHIBITION; RECEPTOR; REPAIR; CELLS;
D O I
10.3748/wjg.v29.i39.5452
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUNDOxaliplatin (Oxa) is the first-line chemotherapy drug for colorectal cancer (CRC), and Oxa resistance is crucial for treatment failure. Prostaglandin F-2 alpha synthase (PGF(2 alpha)) (PGFS), an enzyme that catalyzes the production of PGF(2 alpha), is involved in the proliferation and growth of a variety of tumors. However, the role of PGFS in Oxa resistance in CRC remains unclear. AIMTo explore the role and related mechanisms of PGFS in mediating Oxa resistance in CRC. METHODSThe PGFS expression level was examined in 37 pairs of CRC tissues and paracancerous tissues at both the mRNA and protein levels. Overexpression or knockdown of PGFS was performed in CRC cell lines with acquired Oxa resistance (HCT116-OxR and HCT8-OxR) and their parental cell lines (HCT116 and HCT8) to assess its influence on cell proliferation, chemoresistance, apoptosis, and DNA damage. For determination of the underlying mechanisms, CRC cells were examined for platinum-DNA adducts and reactive oxygen species (ROS) levels in the presence of a PGFS inhibitor or its products. RESULTSBoth the protein and mRNA levels of PGFS were increased in the 37 examined CRC tissues compared to the adjacent normal tissues. Oxa induced PGFS expression in the parental HCT116 and HCT8 cells in a dose-dependent manner. Furthermore, overexpression of PGFS in parental CRC cells significantly attenuated Oxa-induced proliferative suppression, apoptosis, and DNA damage. In contrast, knockdown of PGFS in Oxa-resistant HCT116 and HCT8 cells (HCT116-OxR and HCT8-OxR) accentuated the effect of Oxa treatment in vitro and in vivo. The addition of the PGFS inhibitor indomethacin enhanced the cytotoxicity caused by Oxa. Treatment with the PGFS-catalyzed product PGF(2 alpha) reversed the effect of PGFS knockdown on Oxa sensitivity. Interestingly, PGFS inhibited the formation of platinum-DNA adducts in a PGF(2 alpha)-independent manner. PGF(2 alpha) exerts its protective effect against DNA damage by reducing ROS levels. CONCLUSION PGFS promotes resistance to Oxa in CRC via both PGF(2 alpha)-dependent and PGF(2 alpha)-independent mechanisms.
引用
收藏
页码:5452 / 5470
页数:19
相关论文
共 44 条
[1]   Cucurbiturils: from synthesis to high-affinity binding and catalysis [J].
Assaf, Khaleel I. ;
Nau, Werner M. .
CHEMICAL SOCIETY REVIEWS, 2015, 44 (02) :394-418
[2]   Protein Oxidative Damage at the Crossroads of Cellular Senescence, Aging, and Age-Related Diseases [J].
Baraibar, Martin A. ;
Liu, Liang ;
Ahmed, Emad K. ;
Friguet, Bertrand .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2012, 2012
[3]   Rectal Cancer, Version 6.2020 Featured Updates to the NCCN Guidelines [J].
Benson, Al B., III ;
Venook, Alan P. ;
Al-Hawary, Mahmoud M. ;
Arain, Mustafa A. ;
Chen, Yi-Jen ;
Ciombor, Kristen K. ;
Cohen, Stacey ;
Cooper, Harry S. ;
Deming, Dustin ;
Garrido-Laguna, Ignacio ;
Grem, Jean L. ;
Gunn, Andrew ;
Hoffe, Sarah ;
Hubbard, Joleen ;
Hunt, Steven ;
Kirilcuk, Natalie ;
Krishnamurthi, Smitha ;
Messersmith, Wells A. ;
Meyerhardt, Jeffrey ;
Miller, Eric D. ;
Mulcahy, Mary F. ;
Nurkin, Steven ;
Overman, Michael J. ;
Parikh, Aparna ;
Patel, Hitendra ;
Pedersen, Katrina ;
Saltz, Leonard ;
Schneider, Charles ;
Shibata, David ;
Skibber, John M. ;
Sofocleous, Constantinos T. ;
Stoffel, Elena M. ;
Stotsky-Himelfarb, Eden ;
Willett, Christopher G. ;
Johnson-Chilla, Alyse ;
Gurski, Lisa A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07) :807-815
[4]   Decreased Prostaglandin D2 Levels in Major Depressive Disorder Are Associated with Depression-Like Behaviors [J].
Chu, Cuilin ;
Wei, Hui ;
Zhu, Wanwan ;
Shen, Yan ;
Xu, Qi .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (09) :731-739
[5]  
de Gramont A, 2003, Colorectal Dis, V5 Suppl 3, P10, DOI 10.1046/j.1463-1318.5.s3.3.x
[6]   RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas [J].
Deb, S. ;
Xu, H. ;
Tuynman, J. ;
George, J. ;
Yan, Y. ;
Li, J. ;
Ward, R. L. ;
Mortensen, N. ;
Hawkins, N. J. ;
McKay, M. J. ;
Ramsay, R. G. ;
Fox, S. B. .
BRITISH JOURNAL OF CANCER, 2014, 110 (06) :1606-1613
[7]   Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells [J].
Ekblad, Lars ;
Kjellstrom, Johan ;
Johnsson, Anders .
ANTI-CANCER DRUGS, 2010, 21 (05) :523-531
[8]   Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma [J].
Fung, KM ;
Samara, ENS ;
Wong, C ;
Metwalli, A ;
Krlin, R ;
Bane, B ;
Liu, CZ ;
Yang, JT ;
Pitha, JV ;
Culkin, DJ ;
Kropp, BP ;
Penning, TM ;
Lin, HK .
ENDOCRINE-RELATED CANCER, 2006, 13 (01) :169-180
[9]   Molecular mechanisms of cisplatin resistance [J].
Galluzzi, L. ;
Senovilla, L. ;
Vitale, I. ;
Michels, J. ;
Martins, I. ;
Kepp, O. ;
Castedo, M. ;
Kroemer, G. .
ONCOGENE, 2012, 31 (15) :1869-1883
[10]   Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Glynne-Jones, R. ;
Wyrwicz, L. ;
Tiret, E. ;
Brown, G. ;
Rodel, C. ;
Cervantes, A. ;
Arnold, D. .
ANNALS OF ONCOLOGY, 2017, 28 :22-40